Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas

Modern Pathology

Volumn 28, Issue 3, 2015, Pages 446-456

  Tan, Hsueh Li ^a   Haffner, Michael C ^b   Esopi, David M ^b   Vaghasia, Ajay M ^b   Giannico, Giovanna A ^c   Ross, Hillary M ^a   Ghosh, Susmita ^a   Hicks, Jessica L ^a   Zheng, Qizhi ^a   Sangoi, Ankur R ^d   Yegnasubramanian, Srinivasan ^b   Osunkoya, Adeboye O ^e   De Marzo, Angelo M ^a,b,f   Epstein, Jonathan I ^a,b,f   Lotan, Tamara L ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EL CAMINO HOSPITAL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CYTOKERATIN 14; CYTOKERATIN 15; GLUTATHIONE TRANSFERASE P1; MOLECULAR MARKER; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTEIN; PROTEIN P63; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; CKAP4 PROTEIN, HUMAN; ISOPROTEIN; MEMBRANE PROTEIN;

ARTICLE; BASAL CELL; CLINICAL ARTICLE; CPG ISLAND; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MALE; ONCOGENE C KIT; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SIGNAL TRANSDUCTION; ADENOCARCINOMA; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR;

ADENOCARCINOMA; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU HYBRIDIZATION; MALE; MEMBRANE PROTEINS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS;

EID: 84929613815     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.115     Document Type: Article

References (38)

1. Osunkoya AO, Hansel DE, Sun X, et al. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: Report of 21 cases. Am J Surg Pathol 2008;32:461-467
2. Giannico GA, Ross HM, Lotan T, et al. Aberrant expression of p63 in adenocarcinoma of the prostate: A radical prostatectomy study. Am J Surg Pathol 2013;37:1401-1406
3. Ali TZ, Epstein JI. Basal cell carcinoma of the prostate: A clinicopathologic study of 29 cases. Am J Surg Pathol 2007;31:697-705
4. Toubaji A, Albadine R, Meeker AK, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011;24:1511-1520
5. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011;17:6563-6573
6. Suh EK, Yang A, Kettenbach A, et al. P63 protects the female germ line during meiotic arrest. Nature 2006;444:624-628
7. Wang F, Flanagan J, Su N, et al. RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2012;14:22-29
8. Yegnasubramanian S, Lin X, Haffner MC, et al. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res 2006;34:e19
9. Parsons JK, Saria EA, Nakayama M, et al. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate 2009;69:559-569
10. Uchida K, Ross H, Epstein J, et al. DeltaNp63 isoforms of p63 in aberrant diffuse p63 positive prostate cancer. Mod Path 2012;25:247
11. Romano RA, Ortt K, Birkaya B, et al. An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One 2009;4:e5623
12. Harper ME, Glynne-Jones E, Goddard L, et al. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol 1998; 186:169-177
13. Haffner MC, Aryee MJ, Toubaji A, et al. Androgeninduced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010;42:668-675
14. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011;29:3659-3668
15. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13:519-528
16. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-624
17. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-526
18. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009;22:1083-1093
19. Bismar TA, Yoshimoto M, Vollmer RT, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011;107:477-485
20. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-11737
21. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-1986
22. Pignon JC, Grisanzio C, Geng Y, et al. P63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci USA 2013;110:8105-8110
23. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and metaanalysis. Cancer Epidemiol Biomarkers Prev 2012;21:1497-1509
24. Mills AA, Zheng B, Wang XJ, et al. P63 is a P53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713
25. Yang A, Schweitzer R, Sun D, et al. P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718
26. Signoretti S, Waltregny D, Dilks J, et al. P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-1775
27. Signoretti S, Pires MM, Lindauer M, et al. P63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 2005;102:11355-11360
28. Romano RA, Smalley K, Magraw C, et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012;139:772-782
29. Choi N, Zhang B, Zhang L, et al. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012;21:253-265
30. Wang ZA, Mitrofanova A, Bergren SK, et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 2013; 15:274-283
31. Grisanzio C, Signoretti S. P63 in prostate biology and pathology. J Cell Biochem 2008;103:1354-1368
32. Yi R, Poy MN, Stoffel M, et al. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008;452:225-229
33. Lawson DA, Zong Y, Memarzadeh S, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 2010;107: 2610-2615
34. Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science 2010;329:568-571
35. Stoyanova T, Cooper AR, Drake JM, et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci USA 2013;110:20111-20116
36. Lu TL, Huang YF, You LR, et al. Conditionally ablated pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am J Pathol 2013;182:975-991
37. Nakayama M, Bennett CJ, Hicks JL, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. Am J Pathol 2003;163:923-933
38. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14: 3380-3385. Modern Pathology